Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 2139 (117th)

Medicare Drug Price Negotiation Act

referredUnited States· United States Congress· EN

Introduced

23 March 2021

Last action

24 March 2021 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Doggett, Lloyd [D-TX-37], Sen. Welch, Peter [D-VT], Rep. Bush, Cori [D-MO-1], Rep. Khanna, Ro [D-CA-17], Rep. Pocan, Mark [D-WI-2], Rep. Jayapal, Pramila [D-WA-7], Rep. Cohen, Steve [D-TN-9], Rep. DeLauro, Rosa L. [D-CT-3], Rep. Tlaib, Rashida [D-MI-12], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Neguse, Joe [D-CO-2], Rep. Omar, Ilhan [D-MN-5], Rep. Schakowsky, Janice D. [D-IL-9], Rep. DeFazio, Peter A. [D-OR-4], Rep. DeSaulnier, Mark [D-CA-10], Rep. Grijalva, Raúl M. [D-AZ-7], Sen. Kim, Andy [D-NJ], Rep. Waters, Maxine [D-CA-43], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Bonamici, Suzanne [D-OR-1], Rep. Levin, Andy [D-MI-9], Rep. Jones, Mondaire [D-NY-17], Rep. Lawrence, Brenda L. [D-MI-14], Rep. Yarmuth, John A. [D-KY-3], Rep. Garcia, Sylvia R. [D-TX-29]

Subjects

Healthcare

Source updated

21 January 2026

Healthcare

Summary

Medicare Drug Price Negotiation Act This bill makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs). Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations. If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the median price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost. Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 23 March 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  2. 23 March 2021

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 23 March 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 23 March 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 24 March 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 23 March 2021

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 23 March 2021

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 23 March 2021

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.